BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21055355)

  • 1. [Inhibition of the expression of FHL2 by RNA interference].
    Wang ZY; Zhou L; Ding LH; Lv QJ; Yang X; Ye QN
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Nov; 26(11):1149-51. PubMed ID: 21055355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis.
    Wang J; Yang Y; Xia HH; Gu Q; Lin MC; Jiang B; Peng Y; Li G; An X; Zhang Y; Zhuang Z; Zhang Z; Kung HF; Wong BC
    Gastroenterology; 2007 Mar; 132(3):1066-76. PubMed ID: 17383428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1.
    Sun J; Yan G; Ren A; You B; Liao JK
    Circ Res; 2006 Sep; 99(5):468-76. PubMed ID: 16888242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional gene silencing mediated by chitosan/siRNA nanocomplexes.
    Ji AM; Su D; Che O; Li WS; Sun L; Zhang ZY; Yang B; Xu F
    Nanotechnology; 2009 Oct; 20(40):405103. PubMed ID: 19752491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the FHL2 gene attenuates the formation of atherosclerotic lesions after a cholesterol-enriched diet.
    Chu PH; Yeh HI; Wu HH; Hong RC; Shiu TF; Yang CM
    Life Sci; 2010 Feb; 86(9-10):365-71. PubMed ID: 20096293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mapping of FHL2 transcription activation domain].
    Yan JH; Ye QN; Fang Y; Zhu JH; Huang CF
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):643-8. PubMed ID: 12883635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency in the LIM-only protein Fhl2 impairs skin wound healing.
    Wixler V; Hirner S; Müller JM; Gullotti L; Will C; Kirfel J; Günther T; Schneider H; Bosserhoff A; Schorle H; Park J; Schüle R; Buettner R
    J Cell Biol; 2007 Apr; 177(1):163-72. PubMed ID: 17420295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer.
    Zhang W; Jiang B; Guo Z; Sardet C; Zou B; Lam CS; Li J; He M; Lan HY; Pang R; Hung IF; Tan VP; Wang J; Wong BC
    Carcinogenesis; 2010 Jul; 31(7):1220-9. PubMed ID: 20460358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration.
    König K; Diehl L; Rommerscheidt-Fuss U; Golletz C; Quast T; Kahl P; Kolanus W; Knolle P; Buettner R; Heukamp LC
    J Immunol; 2010 Aug; 185(3):1466-75. PubMed ID: 20592280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast cancer cells.
    Xiong Z; Ding L; Sun J; Cao J; Lin J; Lu Z; Liu Y; Huang C; Ye Q
    IUBMB Life; 2010 Sep; 62(9):669-76. PubMed ID: 20734429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo.
    Qian Z; Mao L; Fernald AA; Yu H; Luo R; Jiang Y; Anastasi J; Valk PJ; Delwel R; Le Beau MM
    Leukemia; 2009 Sep; 23(9):1650-7. PubMed ID: 19369964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-mediated inhibition of E2A-PBX1 reduces EB-1 and Wnt16b expression in 697 pre-B leukemia cells.
    Schwaller J
    Haematologica; 2006 Jun; 91(6):724. PubMed ID: 16769568
    [No Abstract]   [Full Text] [Related]  

  • 13. CREM confers cAMP responsiveness in human steroidogenic acute regulatory protein expression in NCI-H295R cells rather than SF-1/Ad4BP.
    Sugawara T; Sakuragi N; Minakami H
    J Endocrinol; 2006 Oct; 191(1):327-37. PubMed ID: 17065415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities.
    Li M; Wang J; Ng SS; Chan CY; Chen AC; Xia HP; Yew DT; Wong BC; Chen Z; Kung HF; Lin MC
    Glia; 2008 Sep; 56(12):1328-38. PubMed ID: 18615633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
    Heemers HV; Regan KM; Dehm SM; Tindall DJ
    Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective gene suppression using small interfering RNA in hard-to-transfect human T cells.
    Yin J; Ma Z; Selliah N; Shivers DK; Cron RQ; Finkel TH
    J Immunol Methods; 2006 May; 312(1-2):1-11. PubMed ID: 16603179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target.
    Kleiber K; Strebhardt K; Martin BT
    Anticancer Res; 2007; 27(1A):55-61. PubMed ID: 17352216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer.
    Rossi A; Ciafrè S; Balsamo M; Pierimarchi P; Santoro MG
    Cancer Res; 2006 Aug; 66(15):7678-85. PubMed ID: 16885369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of beta protein 1 expression enhances beta-globin promoter activity and beta-globin mRNA levels in the human erythroleukemia (K562) cell line.
    Zoueva OP; Rodgers GP
    Exp Hematol; 2004 Aug; 32(8):700-8. PubMed ID: 15308321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.